Storz Ulrich
Hum Antibodies. 2018 Feb 5;26(2):49-61. doi: 10.3233/HAB-170321.
This article is the second part of a trilogy that discusses IP issues related to anti-Tumor Necrosis factor α (TNFα) biologics. TNFα is the world's most valuable target, with accumulated sales of TNFα biologics of 34 bn USD in 2014. While in the first part of this trilogy, Humira was discussed, this second parts discusses the patent strategies of Enbrel, Remicade, Cimzia and Simponi.
本文是一个三部曲系列的第二部分，该系列讨论与抗肿瘤坏死因子α（TNFα）生物制剂相关的知识产权问题。TNFα是全球最具价值的靶点，2014年TNFα生物制剂的累计销售额达340亿美元。在该三部曲的第一部分中讨论了修美乐（Humira），而在第二部分中则讨论了恩利（Enbrel）、类克（Remicade）、希敏佳（Cimzia）和喜普妙（Simponi）的专利策略。
